Lifeward Ltd. (NASDAQ: LFWD): From ReWalk’s Bionic Walking Pioneer to a High-Risk Neurorehabilitation and Biomedical Platform

Market snapshot at publication

The quote and displayed market capitalization are publication-date snapshots. Financial figures are derived from Lifeward’s 2025 Form 10-K, first-quarter 2026 Form 10-Q, earnings releases and July 2026 Form 8-K.

1. The origin story: a problem worth trying to solve

The ReWalk story began long before Lifeward became a public micro-cap. It began with the gap between what a wheelchair does extraordinarily well and what it cannot provide: upright mobility.

Dr. Amit Goffer, an Israeli engineer and entrepreneur, became quadriplegic after an accident in 1997. He founded the company that would become ReWalk in 2001. At the time, the idea of a wearable powered exoskeleton for personal use sat somewhere between advanced engineering, rehabilitation research and science fiction. Industrial robots were established, but building a battery-powered system that could be worn over a paralyzed user’s legs, respond to intentional movement, remain balanced through crutches and operate in real environments was a different problem entirely.

The device that emerged used powered hip and knee joints, sensors, software, rechargeable batteries and a wrist-worn controller. The user initiated walking through commands and subtle forward shifts of the upper body. The system detected the shift and moved one leg, after which repeated weight transfers created a sequence of steps. The design did not restore neurological function. It provided mechanical ambulation to a carefully selected user who retained sufficient upper-body control.

That distinction matters. ReWalk was never a cure for paralysis, and it never eliminated the wheelchair. It was an assistive medical device that enabled a different mode of movement. Its value could include standing at eye level, walking during selected daily activities, exercise, potential secondary health benefits and a powerful psychological effect. But its practical limitations were present from the start: users still needed crutches, training, suitable terrain, adequate bone density and a body capable of safely carrying out the task.

Development took more than a decade. In 2011, the company launched ReWalk Rehabilitation for hospitals and rehabilitation centers in the United States and Europe. This adjustable multi-user system served two functions. It gave clinics a robotic gait-training tool, and it created a pathway through which potential personal users could discover whether they were suitable candidates. In late 2012, ReWalk Personal began marketing in Europe after CE-mark clearance. By August 2014, the company reported that it had placed 62 Rehabilitation systems and 19 Personal systems and had trained more than 400 users across more than 20,000 hours of use.

Those numbers revealed both sides of the story. They were remarkable for a new category of wearable robotics, but tiny in commercial terms. Even before the IPO, ReWalk was demonstrating that medical-device innovation and scalable adoption are not the same thing.

2. The complete ReWalk-to-Lifeward timeline

3. What made ReWalk innovative

ReWalk’s historical importance rests on three achievements. First, it miniaturized powered lower-limb robotics into a wearable system. Second, it transferred the exoskeleton concept from a laboratory or clinic into personal home and community use. Third, it persuaded regulators to create a pathway for a type of device that had no true predecessor.

The original FDA de novo decision did more than clear one product. It established “powered exoskeleton” as a Class II medical-device category. The authorization described a prescription orthosis placed over the lower limbs and part of the torso, with powered hip and knee movement, a control system, sensors and a required training program. The FDA also identified the central risks: instability, falls, fractures, skin injury, electrical or software failure, misuse and the consequences of improper fitting.

The personal device is custom configured for the user. It does not simply attach to anyone with paralysis. The person must satisfy clinical criteria and complete training. Historically, candidates needed healthy hands and shoulders capable of supporting crutches or a walker, sufficient bone density, no unstable fractures, the ability to stand using a standing frame, suitable height and weight, and generally good health. Cognitive or psychiatric conditions that could interfere with safe operation, severe spasticity, significant contractures, pregnancy and other medical conditions can exclude a candidate.

In use, the technology does something emotionally powerful: it allows a person who ordinarily navigates life from a wheelchair to rise, face others at eye level and take powered steps. That visual impact helped ReWalk attract media attention, research interest and public-market enthusiasm. The stories of users walking at ceremonies, standing at weddings or navigating public environments are not marketing abstractions. They reflect a meaningful change in selected moments of life.

But the system’s engineering success also illustrates why robotics adoption is difficult. The user is not passive. Walking requires concentration, coordinated weight shifting, crutch management and awareness of terrain. Speed is lower than normal walking and usually lower than efficient wheelchair travel. Putting on and removing the device takes time. Batteries, annual inspections, software, replacement parts and service matter. A device that functions in a demonstration must also function after years of real use, across homes, sidewalks, clinics and insurance processes.

Stairs and curbs: a practical rather than cosmetic upgrade

The 2023 FDA clearance for stairs and curbs was important because the original U.S. authorization excluded stair climbing. A personal mobility device that stops at every curb or staircase has an obvious limit in real environments. Lifeward supported the expansion with European real-world experience, including a cohort of 47 users and more than 18,000 stair steps collected over more than seven years.

The feature did not turn ReWalk into unrestricted independent walking. Users still required training and appropriate support. Nevertheless, it reduced a major mismatch between the product’s “community use” aspiration and the built environment. ReWalk 7 later integrated the activation process more seamlessly.

ReWalk 7: modernization rather than a new category

ReWalk 7, cleared in March 2025, is the newest generation of the core platform. Its cloud connectivity can support data capture, service and potentially payer evidence. A crutch-mounted push button reduces dependence on a separate wrist interaction. Customizable walking speeds and a revised interface may improve fitting and user experience. Seamless stair and curb activation reduces workflow friction.

These upgrades are commercially relevant because medical-device adoption is often won through small reductions in inconvenience rather than one spectacular technical leap. ReWalk 7 does not expand the product to every person with spinal cord injury, but it can improve the experience for those who already qualify and make the platform easier for clinics to manage.

4. Why a revolutionary product remained a difficult niche

The largest analytical mistake in the ReWalk story is to calculate the market from the total number of people living with spinal cord injury and then multiply that population by the device price. The real commercial funnel is radically narrower.

Patient eligibility is selective

Many individuals with spinal cord injury cannot safely use a personal lower-body exoskeleton. Cervical injuries may impair the arms and hands needed for crutches. Osteoporosis or low bone density can increase fracture risk. Contractures, severe spasticity, body dimensions, pressure injuries, cardiovascular limitations, balance, cognition and other conditions can exclude or delay use. Even within the eligible population, not everyone wants the device or sees enough daily value to justify the training burden.

The wheelchair is not merely the default because exoskeletons were unavailable. Modern wheelchairs are fast, efficient, familiar and adaptable. An exoskeleton can provide upright exercise and selected ambulation, but it generally does not replace the wheelchair for long-distance mobility, workday efficiency or complex terrain. The relevant question for a patient is therefore not “Would walking be desirable?” It is “Will I use this particular system frequently enough, safely enough and meaningfully enough to justify months of evaluation, fitting and training?”

The price creates an institutional transaction

CMS’s $91,031.93 K1007 purchase fee-schedule amount—commonly rounded to $91,032—illustrates the economic scale. At that level, a ReWalk purchase is not comparable to a consumer wellness device. It is closer to a complex durable-medical-equipment procurement. The sale can involve physicians, therapists, documentation, medical-necessity review, prior authorization, appeals, a payer, a supplier, fitting, training, warranty and ongoing service.

Before broad Medicare reimbursement, many personal systems depended on self-pay, legal settlements, donations, workers’ compensation, veterans’ benefits or case-by-case insurer decisions. That process created long sales cycles and unpredictable revenue recognition. It also meant that demand could exist without becoming booked revenue.

Training is part of the product

ReWalk is not shipped in a box and activated through an app. A user must be evaluated, fitted and trained by qualified personnel. The training network is therefore part of Lifeward’s commercial infrastructure. Every geographic expansion requires more than a distributor: it requires clinical partners capable of screening candidates, teaching safe use and supporting documentation.

This is one reason the Shirley Ryan AbilityLab collaboration and Verita Neuro model matter. Dedicated evaluation days can reduce the number of disconnected steps between interest and qualification. Intensive inpatient training can compress a process that otherwise unfolds over repeated outpatient visits. Neither model guarantees high conversion, but both address a known bottleneck.

Clinical evidence is meaningful but heterogeneous

Published studies support the feasibility of powered-exoskeleton walking and report potential benefits involving physical activity, bowel function, pain, spasticity, body composition and psychosocial well-being. A 2016 meta-analysis found that powered exoskeletons could enable ambulation in real-world settings and generate exercise intensity compatible with prolonged use. Small home and community studies have shown that trained participants can use the device outside the laboratory.

The evidence base nevertheless has limitations: small samples, selected participants, different devices, short follow-up and outcomes that may not translate directly into reduced healthcare costs. Some claimed secondary benefits remain difficult to quantify at the level payers require. An emotional or functional benefit for an individual can be real even when a health-economic model remains uncertain.

Lifeward has also presented long-term safety data. At ASIA 2026, the company reported low fracture prevalence across a global data set and no fractures among a German cohort of 97 users since 2018. Those data are encouraging, but readers should recognize that they were presented by the company and should be assessed alongside peer-reviewed and independent evidence.

Reimbursement solves access, not every commercial problem

Medicare coverage is the most important commercial development in ReWalk’s history, but coverage is not the same as automatic payment. The company still needs medically eligible candidates, physician support, complete documentation, prior authorization where applicable, successful training and a clean claim. Payment timing affects working capital. Denials or requests for additional information can stretch the cycle.

The key metric is therefore not theoretical covered lives. It is the number of reimbursed units delivered per quarter, the time from lead to placement, the cash-collection cycle and the contribution margin after reimbursement, training, service and sales expenses. Lifeward has reported record Medicare placement quarters, but total ReWalk revenue of $8.5 million in 2025 remained slightly below 2024. The fourth quarter improved by 20%, showing progress, but not yet proving a consistently accelerating curve.

5. The reimbursement odyssey

The Department of Veterans Affairs

The VA became an early institutional leader. Its 2015 national policy created a route for qualified veterans with spinal cord injury to be evaluated, trained and provided with a personal exoskeleton. A 2018 policy revision expanded training access through more VA locations and eligible private rehabilitation centers. The VA pathway was important not only for sales, but because it showed that a national payer could treat an exoskeleton as a legitimate assistive technology rather than a demonstration device.

Even so, VA adoption remained limited by the number of clinically eligible veterans and training availability. A national policy removes a major barrier, but it does not turn a narrow population into a mass market.

Germany: from case-by-case wins to structured procurement

Germany supplied some of the earliest reimbursement victories. Individual accident insurers approved systems, and in 2018 ReWalk 6.0 entered the official medical-aids directory. The listing gave the product a recognized code and established it as an eligible medical aid within statutory health insurance.

Later contracts with major insurers defined the evaluation and procurement process more clearly. The February 2025 BARMER agreement added a formal pathway for 8.5 million beneficiaries. Lifeward said that, after the agreement, approximately 45% of Germany’s statutory-insurance population was covered by insurers with a defined reimbursement process for personal exoskeletons.

Germany is useful as a real-world commercial laboratory. It demonstrates that reimbursement can be built, but also that even a favorable national system requires insurer contracts, medical-service review and extended training. The market became more predictable, not effortless.

Medicare: the milestone that took nearly a decade

When ReWalk went public in 2014, management already recognized that broad U.S. reimbursement was essential. The original IPO filing warned that a CMS decision could take years. That warning proved accurate.

CMS’s 2023 Home Health final rule classified personal exoskeletons under the Medicare brace benefit, effective January 1, 2024. In April 2024, CMS added a $91,031.93 purchase fee-schedule amount for HCPCS code K1007, calculated through gap filling because the technology contained features that could not be described through existing comparable codes.

This solved three foundational questions: benefit category, coding and payment. It allowed physicians and suppliers to pursue claims with a defined national framework. Lifeward reported that Medicare Administrative Contractors began approving claims and that placements subsequently reached record quarterly levels.

The commercial test now shifts from policy creation to execution. Lifeward must build a repeatable funnel and prove that the economics of each reimbursed placement are attractive after all associated costs. It must also extend the logic beyond traditional Medicare. Coverage decisions by Aetna, Humana and UnitedHealthcare Medicare Advantage plans, representing approximately 16 million covered lives according to Lifeward, are part of that expansion.

6. Beyond ReWalk: the portfolio Lifeward assembled

ReStore: elegant technology, limited commercial weight

ReStore came from soft-robotics work associated with Harvard’s Biodesign Lab. Instead of a rigid frame powering the hips and knees, ReStore uses a lightweight textile structure and cable-driven assistance around the ankle to help people with hemiplegia or hemiparesis after stroke during supervised rehabilitation.

The FDA cleared ReStore in June 2019 for use in rehabilitation institutions by patients who can already walk at least five feet with no more than minimal to moderate assistance. The device is therefore a therapy tool, not a personal system for non-ambulatory community use.

Clinical publications have reported improvements in walking speed and distance, including a randomized study and follow-up work suggesting that gains after intensive training can persist beyond the treatment period. The technology is scientifically credible and potentially useful to therapists.

Commercially, however, ReStore did not become the scale engine investors once imagined. Rehabilitation centers must decide whether a specialized robotic system improves outcomes or workflow enough to justify capital spending, staff training and maintenance. The company recorded obsolete ReStore inventory write-downs during its 2025 manufacturing transition. That does not mean the clinical concept failed; it means the product’s commercial relevance has been modest relative to the resources once expected.

MYOLYN MyoCycle: portfolio breadth without ownership leverage

Lifeward began distributing MYOLYN functional electrical stimulation cycles in 2020. FES cycling activates paralyzed or weakened muscles through electrical impulses, allowing therapeutic cycling in clinics or at home. The product fits the company’s neurological rehabilitation channels and was available through VA pathways.

But distribution products typically provide less strategic control and lower long-term leverage than proprietary platforms. MyoCycle revenue fell 50% to approximately $0.6 million in 2025 and fell 90% year over year in the fourth quarter as Lifeward moved away from an exclusive arrangement and prioritized proprietary products. The decline is a reminder that adding catalog items can expand revenue temporarily without changing the company’s underlying economics.

AlterG: the acquisition that changed the revenue base

In August 2023, ReWalk paid approximately $19 million in cash to acquire AlterG, with additional earnouts tied to revenue growth. AlterG’s Anti-Gravity systems use differential air pressure to reduce a user’s effective body weight during treadmill walking or running. The technology originated from NASA-related concepts and is installed across rehabilitation clinics, hospitals, sports programs and performance facilities.

The strategic logic was understandable. AlterG served a much broader population than personal exoskeletons, had an installed base exceeding 4,000 facilities worldwide, generated recurring service revenue and gave ReWalk a larger commercial platform. It also diversified the company away from a single product whose sales depended on individual reimbursement.

The acquisition transformed reported revenue. Lifeward’s total revenue rose from $13.9 million in 2023, which included only a partial period of AlterG ownership, to $25.7 million in 2024. But the acquisition did not produce profitability. AlterG revenue then fell 18% to $12.9 million in 2025, and Q1 2026 shipments were constrained by working-capital and sourcing issues.

This is a critical execution issue. Capital equipment requires inventory, components and manufacturing commitments before cash is collected. Lifeward disclosed approximately $10.4 million in non-cancelable purchase obligations due within one year at March 31, 2026. At the same date, cash was $11.4 million. The figures are not directly netted against one another, but they show why working-capital management is central to the company’s survival and growth.

Lifeward closed AlterG’s Fremont operations and transferred production to contract manufacturer Cirtronics. It also transitioned ReWalk production away from Sanmina toward an in-house model. These moves may reduce costs, but manufacturing transitions can cause shipment timing problems, inventory write-downs, quality risk and lower factory absorption. Q1 2026’s 34.2% gross margin, down from 42.2% a year earlier, reflected lower volume, fixed-overhead absorption, tariffs and currency effects.

7. The rebrand: why ReWalk became Lifeward

The Lifeward name was introduced operationally in January 2024, with the Nasdaq ticker changing from RWLK to LFWD. The legal corporate name changed in September 2024. The rebrand was more than cosmetic. “ReWalk Robotics” described one flagship product; “Lifeward” was intended to describe a continuum of rehabilitation and recovery technologies.

The timing made strategic sense after AlterG. The company now sold rigid exoskeletons, a soft exosuit, anti-gravity treadmills and FES cycles. A broader identity could help cross-selling, channel partnerships and future acquisitions.

Yet rebranding creates a risk when the company’s strongest recognition remains attached to the original product. ReWalk is a memorable category pioneer. Lifeward is less specific. The company must preserve ReWalk’s credibility while showing that the parent organization can allocate capital across multiple technologies. The 2026 move into oral biologics pushes that challenge much further: Lifeward is no longer merely a diversified rehabilitation-device company.

8. The 2026 upper-body exoskeleton initiative

In February 2026, Lifeward agreed to acquire intellectual property, prototypes and related assets from Finland-based Skelable. The consideration was modest—approximately $480,000 in Lifeward equity payable in milestone-based installments plus nominal cash—but the strategic ambition is substantial.

The platform is designed to assist weakened or paralyzed arms and hands, initially targeting people with upper-limb impairment after stroke. The engineering group joining the project brings extensive exoskeleton and wearable-robotics experience. Lifeward has said the system integrates artificial-intelligence capabilities and could reach commercial launch approximately 18 to 24 months after continued development and regulatory approvals.

Upper-body rehabilitation may be commercially attractive for several reasons. Stroke is far more common than the subset of spinal cord injury suitable for ReWalk Personal. Loss of arm and hand function directly affects eating, dressing, hygiene, transfers, work and independent living. A device that assists repeated task-specific movement could fit rehabilitation clinics and, eventually, home therapy.

The reimbursement landscape may also be more favorable than starting from zero. CMS already has powered upper-limb orthosis pathways, although Lifeward will still need the correct product classification, clinical evidence, coding and coverage. The company believes it can reuse its regulatory, clinical and payer capabilities.

Investors should not treat the 18-to-24-month target as a guaranteed launch. The acquired technology was not a finished commercial product. Lifeward must complete engineering, usability, verification, clinical work, manufacturing design and regulatory submission. It must also prove that the device provides enough functional improvement to justify its price and therapist workflow. The program is promising precisely because it addresses a broader need, but it remains a development asset.

9. The Oramed transaction: a new company inside the old company

The most dramatic change in Lifeward’s history may not be an exoskeleton at all. In March 2026, the company closed a strategic transaction with Oramed Pharmaceuticals and acquired Oratech Pharma, including the Protein Oral Delivery technology platform and the ORMD-0801 oral-insulin program.

The platform is designed to deliver protein drugs orally rather than through injection. Oral insulin is the lead asset. The scientific objective is compelling: deliver insulin through the gastrointestinal tract in a way that exposes the liver before the peripheral circulation, potentially more closely approximating natural physiology and allowing earlier treatment in type 2 diabetes.

Oramed previously ran a large Phase 3 program that did not meet its primary endpoint. The new strategy is based on analyses intended to identify a more responsive population and optimize the trial design. Lifeward has described a planned 60-patient U.S. study. Oramed is expected to provide clinical-development and project-management services and to fund much of the development effort under the transaction structure.

This arrangement gives Lifeward optionality without requiring it to build an entire drug-development organization immediately. It also creates a path to value that is not tied to rehabilitation capital equipment. If a targeted oral-insulin study produces convincing data, the platform could attract partnership interest far beyond Lifeward’s current scale.

The risks are equally clear. Oral delivery of biologics is scientifically difficult. A prior Phase 3 failure cannot be ignored. Small post-hoc subgroups can generate hypotheses that do not reproduce prospectively. Drug trials operate on different timelines, regulatory standards and capital requirements than medical devices. The company now needs to communicate two very different stories to investors while maintaining focus on the commercial business that funds part of its operations.

Transaction economics and governance

The transaction was not a simple technology purchase. Lifeward issued 1,250,363 ordinary shares and pre-funded warrants for 1,006,113 shares, plus 1,296,296 freestanding warrants with a $5.40 exercise price. The company agreed to future revenue-sharing payments. The accounting value of the acquired assets was approximately $12.4 million, including $6.5 million of cash, approximately $1.0 million of prepaid clinical-trial services and $4.9 million allocated to in-process research and development, which was expensed immediately.

At closing, Oramed received instruments representing up to 49.99% of Lifeward’s fully diluted equity, while the number of ordinary shares issued at closing was limited to no more than 45% of outstanding ordinary shares immediately after closing. Certain board members are affiliated with Oramed. This concentration can align a strategic sponsor with the company, but it also gives Oramed significant economic and governance influence.

In parallel, Lifeward entered a financing agreement providing up to $20 million of senior secured convertible notes, including $10 million issued at closing, together with warrants. The March notes bear 8% interest, mature in March 2029 and are convertible at $5.40 per share, subject to terms and adjustments.

Management has discussed up to $47 million of potential financing support associated with the broader Oramed framework. Readers should not interpret that headline as $47 million of unrestricted cash already on the balance sheet. The total includes conditional or structured financing components, and each component can carry debt, conversion or ownership consequences.

10. The July 2026 financing: capital with a significant equity shadow

On July 6, 2026, Lifeward closed an additional financing involving $5.58 million in senior secured convertible notes and matching warrants. The company may issue a second $5.58 million tranche if it satisfies customary conditions and one of two commercial or market triggers.

The first trigger requires at least a 150% increase in ReWalk unit sales, measured in dollars, relative to the relevant trailing-twelve-month comparison. The second requires LFWD shares to close at or above $13.80 for ten consecutive trading days before the additional closing.

The notes mature three years after issuance and bear 8% annual interest, rising to 15% after an event of default. They convert at an initial $5.40 per share. The warrants cover up to 100% of the shares into which the notes were initially convertible, also at $5.40, and remain exercisable for five years. Conversion and exercise are subject to 4.99% beneficial-ownership limitations for each purchaser and a 19.99% exchange cap unless shareholders approve issuance above that limit.

The financing is not inherently negative. A small loss-making company needs capital to build inventory, support claims, fund upper-body development and maintain operations. The structure also ties the second tranche partly to strong ReWalk execution. But the notes are secured, carry interest and create a substantial number of potential shares and warrants at a price below the publication-date market quote.

For LFWD, dilution analysis cannot stop at basic shares outstanding. At March 31, 2026—before the July financing—the company said that warrants, pre-funded warrants, options and convertible notes covering approximately 6.97 million shares were excluded from diluted earnings-per-share calculations because the company reported a loss. “Anti-dilutive” in accounting does not mean economically irrelevant. It only means those instruments were not included in the loss-per-share denominator for that period.

11. Financial history: innovation has not yet become self-funding growth

2024: the reimbursement and acquisition surge

2024 was the strongest revenue year in the company’s history. Total revenue reached $25.7 million, compared with $13.9 million in 2023. ReWalk sales rose 130%, benefiting from Medicare claims and the establishment of a national reimbursement rate. AlterG contributed a full year instead of only the post-acquisition period.

But operating expenses and losses remained high. Lifeward recorded a large impairment charge associated with acquired intangible assets, and operating cash use reached approximately $21.7 million. The business demonstrated that it could grow revenue, but not yet that the growth would produce operating leverage.

2025: restructuring and a setback in the top line

Revenue fell to $22.0 million. ReWalk Personal generated approximately $8.5 million, down 3%. AlterG generated $12.9 million, down 18%, partly because a large international distributor had ordered more heavily in 2024 and was expected to resume in 2026. MyoCycle produced approximately $0.6 million, down 50%.

Gross margin improved on a reported basis to 38.2% from 32.0%, although adjusted gross margin fell to 40.9% from 42.7%. Total operating expenses declined 25% to $28.1 million, helped by restructuring, lower R&D after major device programs and more efficient sales and reimbursement spending. Adjusted operating loss narrowed to $15.1 million. Operating cash use improved to $16.8 million from $21.7 million.

The direction of expenses was encouraging, but the company still consumed cash at a rate that required financing. Lifeward ended 2025 with only $2.2 million in unrestricted cash and substantial doubt about its ability to continue as a going concern without additional capital.

Q1 2026: better cash, weaker operations, complex accounting

First-quarter revenue fell to $3.9 million from $5.0 million. AlterG weakness was the primary cause, while ReWalk improved. Gross margin fell to 34.2% because of lower volume, manufacturing overhead, tariffs and foreign exchange.

GAAP operating loss widened to $10.3 million, but approximately $4.9 million was a one-time acquired in-process R&D charge related to Oratech, and about $0.6 million represented transaction expenses. Non-GAAP operating loss was approximately $4.6 million, roughly consistent with the prior-year period.

Cash increased to $11.4 million, largely because the Oratech acquisition brought $6.5 million and the financing supplied additional capital. Operating cash use improved to $3.7 million from $5.5 million. That is a positive operational trend, but one quarter does not establish a sustainable runway, especially with purchase commitments, secured debt and new development programs.

Balance-sheet details that deserve more attention

• Inventory: $6.3 million at March 31, 2026. This is substantial relative to quarterly revenue and creates both fulfillment capacity and obsolescence risk.
• Accounts receivable: $5.7 million. Cash conversion matters because reimbursements and capital-equipment sales can have extended collection cycles.
• Customer concentration: one customer represented 62% of the company’s trade-receivable credit exposure at March 31, 2026.
• Purchase obligations: approximately $10.4 million, all scheduled within one year, primarily for ReWalk and AlterG manufacturing requirements.
• Debt and derivative complexity: convertible notes, derivative liabilities and warrant liabilities can create interest expense and non-cash fair-value volatility.
• Accumulated deficit: $284.7 million at the end of 2025, demonstrating that repeated equity raises have funded a long path without cumulative profitability.

12. Management, execution and governance

Larry Jasinski led ReWalk for more than a decade, including the IPO, FDA clearance, VA policy, German reimbursement, the AlterG acquisition and the early Medicare breakthrough. In 2025, Mark Grant moved into the chief executive role as the company shifted from founder-era commercialization toward restructuring and strategic expansion.

The transition is important because the required management skill set has changed. Lifeward must now operate manufacturing, direct sales, distributors, reimbursement teams, rehabilitation partnerships, a new upper-body development program and a clinical-stage drug platform. It must manage debt covenants and a highly complex capitalization table while maintaining Nasdaq compliance.

Bob Marshall became chairman in January 2026, bringing public-company finance experience from Lantheus and Zimmer Biomet. Almog Adar serves as chief financial officer. Dr. Keith Rose joined as chief medical officer in May 2026 to support both the medical-device portfolio and biomedical pipeline.

Oramed’s ownership and board representation create an unusual governance structure. The relationship can provide capital, scientific expertise and transaction discipline. It can also create related-party considerations and strategic dependence. Minority shareholders should monitor how Lifeward allocates resources between commercial neurorehabilitation products and the POD pipeline, how related-party service arrangements are priced, and whether future transactions preserve independent board oversight.

13. Commercial strategy from here

Build a direct-to-patient funnel for ReWalk

Lifeward’s first priority is to turn coverage into placements. The company’s 2025 restructuring created a hybrid U.S. model organized around direct-to-patient engagement, capital-equipment sales and payer capabilities. A successful funnel should identify eligible candidates earlier, guide them through physician documentation, connect them with training centers and reduce claim errors.

Dedicated clinic days at Shirley Ryan AbilityLab are a practical experiment. They can concentrate patient evaluations, therapist expertise and device demonstrations. The model could be replicated at other major spinal-cord-injury centers if it improves conversion and reduces cycle time.

Use channel partners where a direct model is too expensive

The Verita Neuro agreement offers a partner-led route into Mexico, Thailand and the United Arab Emirates. Verita’s inpatient programs can integrate device training into an intensive rehabilitation stay. This may be better suited to international self-pay or medical-tourism populations than the slower outpatient reimbursement model used in the United States and Germany.

The advantage is capital efficiency. The risk is limited control over sales quality, patient selection and brand positioning. Lifeward must ensure that ReWalk is presented as a regulated mobility and rehabilitation device, not as proof of neurological restoration.

Restore AlterG growth

AlterG remains Lifeward’s largest product line. Stabilizing sourcing, production and distributor ordering is essential. The company introduced the lower-cost NEO platform to broaden access, but rehabilitation clinics still face capital budgets and competing equipment priorities.

Management needs to show that the 2025 decline and Q1 2026 weakness were temporary timing and working-capital problems rather than declining demand. Investors should watch unit shipments, backlog, service revenue, gross margin and the resumption of international distributor orders.

Reduce device cost and improve gross margin

Lifeward has stated that R&D will include material-cost reductions for ReWalk and AlterG. This is strategically important. Reimbursement creates a ceiling on available revenue per placement, so margin expansion depends on lower component cost, efficient manufacturing, fewer service events, better inventory planning and a shorter sales cycle.

Cloud-connected devices may help predictive maintenance and usage evidence. Data can support payers, improve service and identify whether users remain active after training. The commercial value of connectivity will depend on whether Lifeward turns it into lower costs or stronger reimbursement, not simply whether the feature exists.

14. Competitive landscape

Medical exoskeletons compete across several categories: rigid systems for spinal cord injury, clinic-based gait-training robots, soft exosuits and emerging self-balancing personal systems. Competitors and adjacent developers have included Ekso Bionics, Indego-related platforms, Wandercraft, Ottobock-linked technologies and a growing field of research-stage wearable robotics.

ReWalk’s strongest advantages are history, regulatory experience, personal-use clearance, reimbursement infrastructure and an established training network. Its weaknesses are dependence on crutches, selective patient eligibility, slow adoption and a company balance sheet far smaller than many medical-device competitors.

The wheelchair remains the most important functional competitor. Any personal exoskeleton must offer enough incremental health, independence or life-experience value to justify cost and complexity. Future self-balancing systems could improve the category’s utility by reducing reliance on crutches, but they may also raise cost, weight and regulatory risk.

AlterG competes with standard treadmills, aquatic therapy, body-weight-support systems and other rehabilitation equipment. Its differential-air-pressure technology is differentiated, but clinic budgets are finite. ReStore competes with conventional therapy, electrical stimulation, treadmill training and other robotic gait tools.

The upper-body program will face devices ranging from passive arm supports to powered rehabilitation robots. Its commercial opportunity may be larger, but so will the need to prove that assistance translates into useful functional recovery or independence.

15. Catalyst map: what can change the Lifeward story

16. Bull case

17. Bear case

18. Red flags that should not be minimized

19. What to monitor each quarter

1. ReWalk revenue and units: distinguish reimbursed placements from demos, rehabilitation units and timing effects.
2. Lead conversion: watch whether direct-to-patient and Shirley Ryan programs shorten the funnel.
3. Accounts receivable and cash collection: revenue quality matters as much as bookings.
4. AlterG shipments: determine whether the 2025 decline and Q1 2026 weakness were temporary.
5. Gross margin: look for evidence that manufacturing transitions and cost-reduction projects are working.
6. Operating cash burn: compare cash use with management’s claims of a path to positive cash flow.
7. Inventory and purchase commitments: excessive inventory can become an expensive warning sign.
8. Basic and fully diluted capitalization: update the share count after every note conversion, warrant exercise and registration statement.
9. Upper-body milestones: insist on specific engineering and regulatory progress rather than repeating the launch target.
10. Oral-insulin trial status: confirm registration and prospective design before assigning value to the asset.
11. Related-party disclosures: review Oramed transactions, services, board relationships and revenue-sharing obligations.
12. Nasdaq compliance: the 2026 reverse split restored the bid price, but sustained compliance still depends on market value and shareholder support.

20. Valuation framework without a price target

Lifeward cannot be valued responsibly through a single revenue multiple. It contains several assets with different risk profiles:

• ReWalk: a reimbursed but narrow personal medical-device franchise whose value depends on placement growth and contribution margin.
• AlterG: a broader capital-equipment and service business with a meaningful installed base but recent revenue volatility.
• ReStore and MyoCycle: smaller portfolio products with limited evidence of strategic value at current revenue levels.
• Upper-body exoskeleton: a pre-commercial development option that should be probability-adjusted for technical, regulatory and commercial risk.
• POD/oral insulin: a clinical-stage pharmaceutical option with potentially large upside and equally large scientific uncertainty.
• Capital structure: secured debt, convertible notes, pre-funded warrants, transaction warrants, legacy warrants and revenue sharing that must be deducted or modeled.

A sum-of-the-parts approach is more logical, but only after constructing a fully diluted share count. Investors should model several conversion and exercise scenarios rather than assuming every instrument either converts immediately or disappears. Cash proceeds from warrant exercise can offset dilution, but cashless-exercise provisions, ownership caps and market prices affect the outcome.

The apparent relationship between a roughly $13.6 million displayed market cap and $22 million of annual revenue may look compelling. It is not a sufficient valuation argument. The company’s losses, debt, obligations and potential shares explain part of the discount. The opportunity exists only if Lifeward can create enterprise value faster than it creates new claims on that value.

21. Bottom line

Lifeward’s history deserves more respect than its stock chart suggests. ReWalk was a legitimate medical breakthrough. It helped create a regulatory category, gave selected people with spinal cord injury a way to stand and walk, and forced payers to confront whether robotic mobility could qualify as a reimbursable medical benefit.

The company also demonstrates why pioneering a category can be financially punishing. ReWalk spent years building technology before reimbursement existed. Each sale required clinical and administrative infrastructure. The eligible market was smaller than headline spinal-cord-injury statistics implied. The business repeatedly raised capital while waiting for policy to catch up.

That policy has now moved. Medicare’s brace classification and $91,031.93 K1007 purchase fee-schedule amount are real. German statutory-insurance contracts are real. ReWalk 7 is a more practical device. Medicare Advantage expansion, Shirley Ryan clinic days and international distribution create a better commercial structure than ReWalk possessed during most of its public history.

But Lifeward is not a clean turnaround. AlterG has not yet produced stable growth or profitability. Cash burn remains high. Manufacturing and working-capital constraints have affected shipments. The Oramed transaction and July financing have made the company better funded but much more complex and potentially dilutive. The POD platform may eventually be valuable, but it also shifts the narrative from a focused medical-device company to a hybrid biomedical micro-cap.

The next phase will be decided by execution rather than invention. Lifeward no longer needs to prove that an exoskeleton can make a paralyzed user walk. It needs to prove that a reimbursed exoskeleton can be sold repeatedly and profitably; that AlterG can generate dependable cash; that an upper-body product can reach market on realistic terms; and that oral insulin can create strategic value without overwhelming the company.

For readers following LFWD, the right stance is neither to dismiss ReWalk as a failed novelty nor to treat every covered-life announcement as the beginning of mass adoption. The technology has earned credibility. The business model is still earning it.

Primary and high-quality research sources